Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent implosion of Novo’s partnership with telehealth firm Hims & Hers suggests there is ...

Semaglutide — better known by its brand names Ozempic (for diabetes) and Wegovy (for weight loss) — received FDA approval in 2017. Since then, U.S. prescriptions have surged from roughly 6.1 billion ...

Still life of Ozempic and Wegovy. Both are injectable prescription weight loss medicines. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) As demand surges for semaglutide ...

Please provide your email address to receive an email when new articles are posted on . Speakers at a congressional briefing highlighted safety concerns around counterfeit GLP-1 drugs. A white paper ...

A Delaware federal judge dismissed a lawsuit brought by Eli Lilly, the maker of the blockbuster weight loss drugs Mounjaro and Zepbound, against a telehealth company it accused of “deceptive” ...

Novo Nordisk veteran Maziar Mike Doustdar—who is set to assume the role of CEO on Thursday—will have his work cut out turning things around at the Danish drugmaker, which is facing a commercial ...

High demand and cost of legitimate GLP-1 drugs like Ozempic and Wegovy have fueled a counterfeit market. Consumers are urged to be cautious when purchasing GLP-1 drugs online and to report any ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. The U.S. Food and Drug Administration (FDA) recently ...